Mansoura Medical Journal
Volume 42

Issue 1

Article 4

4-1-2013

LONG-TERM STUDY OF ERYTHROPOIETIN, LOSARTAN, AND
COMBINATION IN STREPT- OZOTOCIN-INDUCED DIABETIC RATS
Rehab Ashour
Department of Clinical Pharmacology

Abd El-Motaal Fouda
Department of Clinical Pharmacology

Mohamed Saad
Department of Clinical Pharmacology

Farida El-Banna
Department of Clinical Pharmacology

Fatma Moustafa
Department of Pathology Pharmacology Faculty of Medicine, Mansoura University

Follow this and additional works at: https://mmj.mans.edu.eg/home

Recommended Citation
Ashour, Rehab; Fouda, Abd El-Motaal; Saad, Mohamed; El-Banna, Farida; and Moustafa, Fatma (2013)
"LONG-TERM STUDY OF ERYTHROPOIETIN, LOSARTAN, AND COMBINATION IN STREPT- OZOTOCININDUCED DIABETIC RATS," Mansoura Medical Journal: Vol. 42 : Iss. 1 , Article 4.
Available at: https://doi.org/10.21608/mjmu.2020.124887

This Article is brought to you for free and open access by Mansoura Medical Journal. It has been accepted for
inclusion in Mansoura Medical Journal by an authorized editor of Mansoura Medical Journal. For more information,
please contact taboelsaad@mans.edu.eg.

Ashour et al.: LONG-TERM STUDY OF ERYTHROPOIETIN, LOSARTAN, AND COMBINATION IN S

Rehab H. Ashour et al ....

45

LONG-TERM STUDY OF ERYTHROPOIETIN,
LOSARTAN, AND COMBINATION IN STREPTOZOTOCIN-INDUCED DIABETIC RATS
By
Rehab H. Ashour*, Abd El-Motaal Fouda*,
Mohamed Ahdy A. Saad*, Farida Mohamed A.
El-Banna*, Fatma Al-Husseiny Moustafa**

From
Department of Clinical Pharmacology*, Depatment of Pathology**,
Faculty of Medicine, Mansoura University

ABSTRACT
Recombinant human erythropoietin (rHuEPO) has emerged as a new
renoprotective agent against various
acute kidney injuries. Experience
with rHuEPO in chronic kidney injuries is so far limited and conflicting
results were obtained. In the present
study, we addressed to evaluate the
long-term renal effects of rHuEPO in
diabetic nephropathy (DN) of rats in
relation to novel hypoxia theory and
endogenous EPO secretion.
We
compared rHuEPO to a standard
drug, losartan (LSR), and the possibility of add-on therapy was also
tested. Thirty-four male SpragueDawley rats were randomly divided
into five groups: control-naïve group,
untreated diabetic group, EPO45
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treated diabetic group (150 U/kg,
S.C., TIW), LSR-treated diabetic
group (5 mg/kg/day), and EPO-LSRtreated diabetic group. Drug treatment was started one week after
streptozotocin (STZ) injection and
continued for twenty-eight weeks.
STZ-treated diabetic rats developed
progressive albuminuria, renal dysfunction, and significant glomerular
change 28 weeks after induction of
diabetes. Chronic administration of
rHuEPO alone or in combination with
LSR to the STZ-induced diabetic rat
did not show beneficial effect on DN
evolution, inspite of improving diabetic-renal hypoxia. The best beneficial effect on DN evolution was obtained by LSR sole therapy based on
renal function evaluation, albuminuMANSOURA MEDICAL JOURNAL
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ria, and renal histopathology. Interestingly, administration of LSR either
alone or in combination with rHuEPO
in STZ-induced diabetic rats significantly abolished increased plasma
endogenous EPO. In conclusion, this
study has questioned the renoprotective role of low-dose rHuEPO in
the setting of DN and confirmed that
this low-dose rHuEPO used had adverse effects on blood pressure and
increased hematocrit level.
Key words : Diabetic nephropathy, Erythropoietin, Losartan, Rats.

INTRODUCTION
Diabetic nephropathy (DN) is one
of the most serious complications of
diabetes and a leading cause of endstage renal disease (ESRD) worldwide. In fact, about 44% of new
ESRD cases have a primary diagnosis of diabetes (U.S. Renal Data
System, 2011). The pathogenesis of
DN is complex and implies interactions between different metabolic
and hemodynamic factors that act
concomitantly to activate intracellular
second messengers and various
growth factors such as the prosclerotic cytokines, transforming growth
factor-β (TGFβ-1), connective tissue
growth factor (CTGF), and vascular

endothelial growth factor (VEGF)
(Vinod, 2012). Activation of local renin-angiotensin system (RAS) played
a major role in progression of diabetic glomerulosclerosis (Carey & Siragy, 2003). In addition, the novel hypoxia theory of chronic kidney
disease (CKD) including DN and its
role in progression of renal injury is
well documented (Heyman et al.,
2008). Despite the beneficial effects
of the current strategies in the treatment of DN, based mainly on adequate glycemic control and blockade
of RAS, albuminuria and progression
of renal disease are not completely
halted. Therefore, it is necessary to
explore potential new renoprotective
therapy based on the novel hypoxia
theory.
Erythropoietin (EPO) is a 30.4 kD
acidic glycoprotein hormone that regulates erythropoiesis and primarily
synthesized by renal cortical interstitial fibroblasts (Fisher, 2003). EPO
has been used clinically both as an
erythropoietic stimulating agent in
the treatment of anemia associated
with various pathologies and as a tissue-protective agent in certain clinical settings, e.g. stroke, multiple
sclerosis and acute myocardial infarction (Konstantinopoulos et al.,
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2007). Many studies demonstrated
that EPO or recombinant human
EPO (rHuEPO) protected against injury caused by ischemia/reperfusion
in the brain, vessels, heart, and kidney (Sasaki, 2003). However, few
studies have demonstrated the protective effects of rHuEPO on chronic
renal injury. Clinical experience with
EPO in CKD has been conflicting
with some trials showing a beneficial
effect on renal failure progression;
whereas others have failed to demonstrate any effect (Harris et al.,
2006).
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EPO could be maintained for longer
periods without adverse effects is
not known. Also, the relation between the renal effects of low-dose
EPO and renal hypoxia has not been
investigated. So, the aim of this work
is to evaluate the long-term renal effects of rHuEPO in DN of rats and its
relation to renal hypoxia and endogenous EPO secretion. The effect of
rHuEPO was compared to standard
drug, losartan (LSR), and the effect
of EPO and LSR combination was
also investigated.

MATERIALS AND METHODS
Moreover, the tissue-protective
effect of EPO was linked to the use
of low dose than that used for anemia correction. In animal model for
type 2 diabetes, long-term treatment
with a long-acting erythropoiesisstimulating agent had striking dosage-dependent effects on molecular
pathways of diabetic kidney damage
with low-dosage therapy fully exposed the tissue-protective potential
(Menne et al., 2007). Moreover, in
streptozotocin-induced diabetic rats,
one month treatment with the low
dose rHuEPO attenuated renal injury
beyond its hematopoietic effect
(Toba et al., 2009). Whether this tissue-protective effect of low-dose

Chemicals and drugs :
Streptozotocin (STZ): was obtained from Sigma-Aldrich Chemical
Co., St. Louis, MO, USA. Erythropoietin in the form of epoetin alpha
(EPREX® syringes) was supplied as
a gift from Janssen-Cilag Co., USA.
Losartan (dry powder, 98% activity)
was supplied as a gift from Amriya
Pharmaceutical Industries, Alexandria, Egypt.
Animals
Thirty-four male Sprague-Dawley
rats (8 weeks old, weighing 160 to
200 g) obtained from Medical Experimental Research Center (MERC),
Mansoura Faculty of Medicine were
MANSOURA MEDICAL JOURNAL
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used and included 8 control rats and
26 rats made diabetic by single intraperitoneal injection of STZ (60 mg/
kg) dissolved in citrate buffer (10
mmol/L, pH 4.5). At 1 week post-STZ
injection, induction of diabetes was
confirmed by measuring tail vein
blood-glucose level using GlucoDr™
super sensor glucometer (one touch
technology, Allmedicus, Korea). Rats
with fasting blood glucose level more
than 280 mg/dl were considered diabetic and were included in the study
(Tesch & Allen, 2007).
Rats were kept on a regular 12h
dark/light cycle with free access to
standard rat chow and tap water ad
libitum. The animals were observed
for water intake, food intake, changes in body weight, and general
health status during the 28 weeks
study period. The study design and
protocol was revised and approved
by Mansoura Medical Research Ethics committee.
Experimental Design and Groups
Rats were classified into five
groups: 1) the control-naïve group
(CNT-naïve, n=8), received citrate
buffer only, 2) untreated diabetic
group (DM-unt-28W, n=8), received
single intraperitoneal injection of

STZ as previously described (Tesch
& Allen, 2007) and no drug treatment
for 28 weeks after induction of diabetes, 3) EPO-treated diabetic group
(DM-EPO-28W,
n=6),
received
rHuEPO at 150 U/kg, three times per
week, S.C. (Toba et al., 2009), 4)
LSR-treated diabetic group (DMLSR-28W, n=6) received LSR at 5
mg/kg/day, P.O., dose selected
equals to 56 mg human dose according to (Paget & Barnes, 1964), and
5) EPO-LSR-treated diabetic group
(DM-EPO-LSR-28W, n=6) received
combination of EPO and LSR, in the
same doses. Drug treatment was
started one week after STZ injection
and continued for 28 weeks. Because the study duration was 28
weeks and to avoid animal wastage,
severely diabetic rats with blood glucose level more than 500 mg/dl
(data obtained from pilot study) were
treated daily with low-dose NPH insulin at 4.1±1.4 IU/kg body weight
subcutaneously to maintain body
weight and prevent ketosis without
normalizing hyperglycemia (Gross et
al., 2004).
Every 4 weeks, rats in each group
were weighed and individually
housed in metabolic cage (Nalgene;
Nalge Company, Rochester, NY,
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USA) to allow 24h urine collection
that were analyzed for urinary creatinine (Murray, 1987) and albuminuria
(Schosinsky et al., 1987). Final blood
pressure was measured by indirect
tail-cuff plethysmography with a photoelectric sensor (LE5001 pressure
meter, PanLab Technology for Bioresearch) in non-anaesthetized rats.
At the end of the study, animals
were weighed and anesthetized with
thiopental at dosage 12 mg/100 g
BW (Waynforth & Flecknell, 1998),
laparotomy was done and the left renal vein was exposed, blood samples were collected from the left renal vein by heparinized syringe and
analyzed for renal vein oxygen tension, sodium, and potassium levels
(Rapid Point 400, Bayer). One ml of
blood collected from the heart was
taken in a test tube containing 50µI
EDTA for estimation of complete
blood count (Sysmex) and reticulocytic count (RC). The other portion of
blood samples were centrifuged with
EDTA at 3000 rpm for 10 minutes,
plasma were separated and stored
at -30°C until further biochemical assay.
Blood chemistry
The following parameters were
determined with the use of commer-
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cially available kits: glucose (Trinder,
1969) (BioMed-Glucose L.S, Eng
Chem for lab technology, Hannover,
Germany), insulin (Clark & Hales,
1991) (DRG® Rat Insulin ELISA kit,
DRG Diagnostics, Germany), creatinine (Murray, 1987) (Diamond Diagnostics Company, Hannover, Germany), albuminuria (Schosinsky et al.,
1987) (ABC Diagnostics kits, New
Damietta, Egypt), iron (Garcic, 1979)
(ELI Tech, Zone Industrielle, 61500
SEES France), Total iron binding capacity “TIBC” (Schreiber, 2003) (ELI
Tech Clinical Systems, Zone Industrielle, 61500 SEES France) with calculation of transferrin saturation “TS”
as (iron/TIBC)X100, ferritin (Ng et
al., 1983) (Diametra, Via Garibaldi,
Italy), plasma active-renin concentration (PRacC) (Morganti et al., 1995)
(renin ELISA kit, DRG Diagnostics,
Germany), and EPO concentration
(Jelkmann & Wolff, 1991) (Quantikine Mouse/Rat EPO Immunoassay
ELISA kit, R&D Systems, USA).
Morphologic analysis of renal tissue

For all groups, the kidneys were
perfused in a retrograde fashion
through the abdominal aorta using
saline 0.9% and then 10% neutral
buffered formalin for in situ fixation.
The
kidneys
were
harvested,
MANSOURA MEDICAL JOURNAL
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weighed, cut longitudinally, and send
for pathological evaluation in 10%
neutral buffered formalin. The kidney
specimens were coded, embedded
in paraffin, and sections of 5-µm
thickness were cut and evaluated using hematoxylin and eosin, periodic
acid- Schiff (PAS) reagent, and Masson trichrome stains and examined
by light microscopy.
The glomerular changes developed in untreated diabetic control
group at 28th week after induction of
diabetes included: mesangial matrix
expansion, mesangial hypercellularity, and segmental thickening of
GBM. The lesions were focal (affecting less than 50 % of all glomeruli
per section) in all diabetic groups.
These glomerular changes were
scored according to their absence or
presence as follow: normal (absence
of lesions = score 0); presence of
any one of the above mentioned glomerular lesions (score 1); presence
of two glomerular lesions (score 2);
presence of the three glomerular lesions (score 3). Also, untreated diabetic control group developed tubulo-interstitial
lesions
including
interstitial inflammation, mild interstitial fibrosis and tubular atrophy. Vascular lesions presented as arteriolar

hyalinosis were also mild. Because
tubule-interstitial and vascular lesions were mild, they were scored as
absent (score 0) or present (score
1).
Statistical Analysis
All analyses were conducted using SPSS (version 16.0, SPSS, IL,
USA). The data were tested for
Gaussian distributions by Kolmogorov-Smirnov test. Descriptive statistics were reported as mean ± standard deviation (SD) for continuous
variables or median (min-max), and
frequency for categorical variables.
Differences in continuous variables
were analyzed by one-way analysis
of variance (ANOVA) followed by
posthoc
multiple
comparisons
(Scheffé test). Categorical variables
were analyzed by Kruskal-Wallis H,
Mann-Whitney's, and chi-square or
Fisher exact tests (when appropriate). Statistical analysis of albuminuria was performed by analysis of variance according to a general linear
model for repeated measures. P value < 0.05 was considered statistically significant at confidence interval
95 %.

RESULTS
General characteristics of experimental groups
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All diabetic groups showed significant hyperglycemia (P1 < 0.01), insulinopenia (P1 < 0.001), and increase of KW/BW ratio (P1 < 0.05)
compared to CNT-naïve group. On
the other hand, LSR-treated diabetic
group showed significant decrease
of KW/BW ratio compared to untreated- (P2 < 0.05) and EPO-treated (P3
< 0.01) diabetic groups (table 1).
Renal functions: plasma creatinine and creatinine clearance
All diabetic groups showed significant increase of plasma creatinine
(P1 < 0.001) compared to CNTnaïve group. The LSR -treated diabetic group showed significant decrease of plasma creatinine compared to untreated- (P2 < 0.001) and
EPO-treated (P3 < 0.001) diabetic
groups; but the combination-treated
diabetic group showed significant increase of plasma creatinine (P4 <
0.001) compared to LSR-treated diabetic group (table 1). Untreated-,
EPO-treated,
and
combinationtreated diabetic groups showed significant decrease of creatinine clearance compared to CNT-naïve group
(P1 < 0.01); while, LSR-treated diabetic group showed significant increase of creatinine clearance compared to untreated- and EPO-treated

51

diabetic groups (P2 & P3 < 0.001)
and CNT-naïve group (P1 < 0.01).
The combination-treated diabetic
group showed significant decrease
of creatinine clearance compared to
LSR-treated diabetic group (P4 <
0.001) (table 1).
Albuminuria
All diabetic groups showed progressive significant increase of albuminuria on repeated measures (P <
0.001). In addition, albuminuria was
significantly increased in all diabetic
groups at each time point compared
to CNT-naïve group (P1 < 0.05). Albuminuria of EPO-treated diabetic
group was significantly increased at
the 12th week till the end of the
study compared to untreateddiabetic control group (P2 < 0.001).
LSR-treated diabetic group showed
significant decrease of albuminuria
at the 12th week till the end of the
study compared to untreateddiabetic control group (P2 < 0.01)
and EPO-treated diabetic group (P3
< 0.001). At the 12th week till the
end of the study, combinationtreated diabetic group showed significant decrease of albuminuria compared to untreated-diabetic control
group (P2 < 0.01) and EPO-treated
diabetic group (P3 < 0.001); but, sigMANSOURA MEDICAL JOURNAL
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nificant increase of albuminuria compared to LSR-treated diabetic group
(P4 < 0.01) (figure 1).
Mean Blood Pressure
Untreated-diabetic control group
showed significant decrease of final
Mean Blood Pressure (MBP) compared to control-naïve group (P1 <
0.001). However, final MBP of EPOtreated diabetic group was significantly increased compared to control-naïve and untreated-diabetic
control (P1 & P2 < 0.001) groups. Final MBP of LSR-treated diabetic
group was significantly decreased
compared to control-naïve, untreated-diabetic control, and EPO-treated
diabetic groups (P1, P2, & P3 <
0.001). Also, final MBP of combination-treated diabetic group showed
significant decrease compared to
EPO-treated diabetic group (P3 <
0.001) (table 1).
Plasma active-renin concentration, renal vein oxygen tension, and
electrolytes
Untreated-diabetic control group
showed significant decrease of final
PRacC (P1 < 0.001) compared to
CNT-naïve group. However, EPO,
LSR, and combination-treated diabetic groups showed significant in-

crease of final PRacC compared to
CNT-naïve group and untreateddiabetic control group (P1 & P2 <
0.01). LSR and combination-treated
diabetic groups showed significant
decrease of final PRacC compared
to EPO-treated diabetic group (P3 <
0.05) (table 1).
Untreated diabetic control group,
EPO, and LSR-treated diabetic
groups showed significant decrease
of renal vein oxygen tension compared to CNT-naïve group (P1 <
0.01). While, EPO and LSR-treated
diabetic groups showed significant
increase of renal vein oxygen tension compared to untreated-diabetic
control group (P2 < 0.05). Combination-treated diabetic group showed
significant increase of renal vein oxygen tension compared to untreateddiabetic control group (P2 < 0.001),
EPO-treated diabetic group (P3 <
0.01), and LSR-treated diabetic
group (P4 < 0.01) (table 1).
Untreated diabetic control and
EPO-treated diabetic groups showed
significant decrease of renal vein sodium level compared to CNT-naïve
group (P1 < 0.01). LSR and combination-treated
diabetic
groups
showed significant increase of renal
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vein sodium level compared to EPOtreated diabetic group (P3 < 0.01)
(table 1). Untreated diabetic control
group, EPO, and combinationtreated diabetic groups showed significant increase of renal vein potassium level compared to CNT-naïve
group (P1 < 0.05). LSR-treated diabetic group showed significant decrease of renal vein potassium level
compared to untreated- and EPOtreated diabetic groups (P2 < 0.01,
P3 < 0.05). Combination-treated diabetic group showed significant decrease of renal vein potassium level
compared to untreated-diabetic control group (P2 < 0.05); but significant
increase compared to LSR-treated
diabetic group (P4 < 0.01) (table 1).
Hematological parameters, EPO
concentration, and Iron status
LSR-treated
diabetic
group
showed significant decrease of
RBCs count compared to untreateddiabetic control group (P2 < 0.01).
Untreated diabetic control group
showed significant decrease of RC
compared to CNT-naïve group (P1 <
0.05) (table 2). Untreated- and EPOtreated diabetic groups showed significant increase of final EPO concentration compared to CNT-naïve
group (P1 < 0.001). EPO-treated dia-
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betic group showed significant increase of final EPO concentration
compared to untreated-diabetic control group (P2 < 0.01). LSR and combination-treated
diabetic
groups
showed significant decrease of final
EPO concentration compared to
EPO-treated diabetic group (P3 <
0.01). Combination-treated diabetic
group showed significant decrease
of final EPO concentration compared
to untreated- (P2 < 0.001) and LSRtreated diabetic groups (P4 < 0.05)
(table 2).
Transferrin saturation (TS) and
plasma ferritin was significantly decreased in EPO and combinationtreated diabetic groups (P1 < 0.05)
compared to CNT-naïve group.
EPO-treated diabetic group showed
significant decrease of TS compared
to untreated diabetic group (P2 <
0.05). LSR and combination-treated
diabetic groups showed significant
increase of TS compared to EPOtreated diabetic group (P3 < 0.05).
Plasma ferritin was significantly decreased in untreated-diabetic groups
(P1 < 0.01) compared to CNT- naïve
group (table 2).
Renal histopathology
All diabetic groups showed signifiMANSOURA MEDICAL JOURNAL
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cant increase of glomerular changes
score 28 weeks after induction of diabetes (K-W Chi-square = 42.54, P ≤
0.001) (table 3; P1 < 0.01) compared
to CNT-naïve group (Figure 2). The
LSR-treated diabetic group was the
only group that showed significant
decreased of glomerular changes
score (table 3; P2 < 0.01) compared
to untreated diabetic control group.
No significant interstitial fibrosis
(Fisher's exact tests, P1 = 0.200), inflammation (Fisher's exact tests, P1
= 0.200), or arteriolar hyalinosis
(Fisher's exact tests, P1 = 0.467)
were present in untreated-diabetic
control group (table 3, figure 3).
EPO-treated
diabetic
group
showed significant increase of glomerular changes score (Figure 4)
(table 3; P1 < 0.001), IFTA score
(Fisher's exact tests, P1 = 0.015),
and interstitial inflammation score
(Figure 5) (Fisher's exact tests, P1 ≤
0.001) compared to CNT-naïve
group. In addition, EPO-treated diabetic group showed significant increase of interstitial inflammation
score (Fisher's exact tests, P2 =
0.031) compared to untreated diabetic control group and picture of
acute tubular injury and degeneration (Figure 6) that is not included in

DN pathological classification or
scoring system. LSR-treated diabetic
group showed significant decrease
of IFTA score (Chi-square test =
6.00, P3 = 0.014) and interstitial inflammation score (Chi-square test =
6.00, P3 = 0.014) compared to EPOtreated diabetic group (table 3).
Combination-treated
diabetic
group showed significant increase of
glomerular changes score (Figure 7)
(table 3; P1 < 0.01), IFTA score (figure 8) (Fisher's exact tests, P1 ≤
0.001), interstitial inflammation score
(Fisher's exact tests, P1 = 0.015),
and arteriolar hyalinosis score (Figure 9) (Fisher's exact tests, P1 =
0.003) compared to CNT-naïve
group.
Moreover,
combinationtreated diabetic group showed significant increase of glomerular changes
score (table 3; P4 < 0.05) compared
to LSR-treated diabetic group and
significant increase of IFTA score
(Fisher's exact tests, P2 = 0.031)
compared to untreated-diabetic control group and LSR-treated diabetic
groups (Fisher's exact tests, P4 =
0.002). Also, arteriolar hyalinosis
score was significantly increased
compared to EPO-treated diabetic
groups (Fisher's exact tests, P3 =
0.015) (table 3).

Vol. 42, No. 1 & 2 Jan. & April, 2013

https://mmj.mans.edu.eg/home/vol42/iss1/4
DOI: 10.21608/mjmu.2020.124887

10

Ashour et al.: LONG-TERM STUDY OF ERYTHROPOIETIN, LOSARTAN, AND COMBINATION IN S

Rehab H. Ashour et al ....

55

Figure 1: Effect of Erythropoietin (150 U/kg, S.C., TIW), Losartan (5 mg/kg/day, P.O.), or combination on Albuminuria of Control and Diabetic rats.
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Figure 2: Axial mesangial expansion of 28
weeks untreated diabetic control
group (arrow, PAS stain, X400).

Figure 3: IFTA of 28 weeks untreateddiabetic control group (arrow,
Masson Trichrome stain, X250).

Figure 4: Mesangial hypercellularity of EPO- Figure 5: Interstitial inflammatory infiltrate of
treated diabetic group (arrow,
EPO-treated diabetic group (arPAS stain, X400)
row, PAS stain, X250)
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Figure 6: Tubular injury with sheded apical tubular epithelium of EPO-treated
diabetic group (Hx& E stain,
X400)

Figure 8: Focal interstitial fibrosis of Combination-treated
diabetic
group
(Masson trichrome stain, X250)
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Figure 7: Mesangial expansion with hypercellularity of Combination-treated diabetic group (arrow, PAS stain,
X400)

Figure 9: Hyalinized arterioles of Combination-treated diabetic group (arrow,
PAS stain, X400)
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Abbreviations: Pl Gl, Plasma Glucose; Pl INS, Plasma Insulin; KW/BW, Kidney-to-Body Weight ratio; Pl Cr,
Plasma Creatinine; Cr Cl, Creatinine Clearance; MBP, Mean Blood Pressure; PRacC, Plasma activerenin concentration; RV O2T, Renal Vein Oxygen tension; RV Na+, Renal Vein Sodium level; RV K+,
Renal Vein Potassium level
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DISCUSSION
The present study demonstrated
that long-term administration of
rHuEPO alone or in combination with
LSR to the STZ-induced diabetic rat
for 28 weeks did not show beneficial
effect on DN evolution compared to
LSR sole therapy that had the best
beneficial effect. Inspite of improving
diabetic-renal hypoxia by rHuEPO
alone and combined with LSR, the final renal effects were hazardous in
both groups. These results were
supported by renal histopathological
examination. Strangely, administration of rHuEPO with LSR in STZinduced diabetic rats abolished increased plasma endogenous EPO
observed in rHuEPO alone treateddiabetic group. To our knowledge,
no available experimental studies
have investigated the possible effect
of combined administration of EPO
and LSR in models of DN.
As shown in the present study,
STZ-treated diabetic rats developed
progressive albuminuria, renal dysfunction,
significant
glomerular
changes, and mild tubularinterstitial
fibrosis 28 weeks after induction of
diabetes. These results are in accordance to previous reports demonstrating that single high-dose STZ
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model of type 1 diabetes developed
strong degree of hyperglycemia and
albuminuria with moderate degree of
renal failure and some histologic
changes associated with DN (Tesch
& Allen, 2007 and Rüster & Wolf,
2010).
Several studies reported that
acute pretreatment with rHuEPO preserved renal function against acute
ischemia/reperfusion injury (Chatterjee, 2005). Although the possible renoprotective effect of EPO in the setting of chronic kidney injury is of
major clinical importance, it has not
been settled yet. Previously, the
therapeutic effect of EPO in CKD focused on anemia correction with fulldose EPO that might improve renal
hypoxia and delay progression to
ESRD; however, conflicting results
were obtained in different clinical
trials (Harris et al., 2006). Moreover,
dissociating the tissue-protective effect of EPO from its hematopoietic
effect by the use of lower doses was
tested in preclinical disease models
where chronic treatment with hematologically non-effective dose of darbepoetin, a long-acting rHuEPO analogue, conferred renal vascular and
tissue protection in 5/6 nephrectomy
remnant kidney model in the rat
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(Bahlmann et al., 2004). However,
escalating doses of darbepoetin attenuated the protective effects on
the remnant kidney tissue and even
worsen microvascular renal injury,
that is, glomerulosclerosis (Fliser et
al., 2006).
In our study, we used rHuEPO in
the same dose used by Toba et al.
(2009); as they reported that neither
blood pressure nor hematocrit (Hct)
was affected by the administration of
rHuEPO in a dosage of 150 U/kg,
TIW, SC for 4 weeks. Contrarily, our
results showed that chronic administration of this low dose of rHuEPO
for 28 weeks led to elevation of
blood pressure and Hct in diabetic
and control non-diabetic rats (data
not shown).
In agreement of our results that
failed to demonstrate beneficial effects of long-term low-dose rHuEPO
administration, an earlier experimental study reported that vigorous correction of anemia with rHuEPO (25
U, IP, twice weekly) in rats with renal
ablation is associated with striking
acceleration of glomerular injury and
greater severity of proteinuria such
that values were higher than those in
control rats which was explained by

aggravation of systemic and glomerular hypertension (Garcia et al.,
1988).
In contrast to our results, beneficial effects were reported in genetic
experimental models of type 2 diabetes (i.e., the leptin receptor knockout db/db mouse), where chronic administration
of
continuous
erythropoietin receptor activator for
14 weeks had beneficial dosedependent effects on molecular
pathways of diabetic kidney damage
including TGF-β1 and nephrin expression in renal tissue. However,
only the non-hematologically effective low-dose was clinically renoprotective, whereas high-dose aggravated albuminuria despite clear-cut
beneficial molecular effects. Moreover, phlebotomy in high-dose treated
mice preserved its tissue protective
effect (Menne et al., 2007). Also, one
month treatment with rHuEPO (150
U/kg, TIW, SC) in STZ-induced diabetic rats significantly attenuated
proteinuria, renal fibrosis, and renal
elevation in mRNA for TGF-β, osteopontin and adhesion molecules, with
normalization of renal function.
These beneficial effects of chronic
rHuEPO treatment occurred beyond
hematopoiesis (Toba et al., 2009).
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large shunt-like pores in glomerular
In a randomized, double-blind,
multicenter, controlled trial, olmesartan (40 mg once daily for a median
of 3.2 years) increased the time to
onset of microalbuminuria by 23% in
patients with type 2 diabetes, even
when blood-pressure control is excellent in olmesartan and placebo
groups (Haller et al., 2011). It is well
known from studies in diabetic and

membrane in

DN was partly re-

stored by treatment with losartan 50
mg/day for 2 months (Andersen et
al., 2000).
In the present study, administration of EPO alone for 28 weeks led
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naïve and untreated-diabetic control
groups. However, administration of
LSR for 28 weeks in diabetic rats
significantly lowered final MBP level.
Administration of EPO in combination with LSR prevented EPOinduced increase of final MBP that
remained significantly lower compared to EPO alone-treated diabetic
group. In agreement of our results,
one study in rats showed that EPO
administration (150 U/kg BW, TIW)
for 6 weeks caused an increase in
blood pressure in spontaneously hypertensive rats, but not in Wistar
Kayato rats, suggesting genetically
related susceptibility (Panzacchi et
al., 1997). Also, it has been demonstrated that long-term administration
of EPO in normal human subjects
and patients with CKD provokes arterial hypertension which occurs independently of EPO’s hematopoietic
effect (Krapf & Hulter, 2009). Moreover, EPO treatment with prolonged
low-dose or high doses for 3 days induced an increase in total peripheral
resistance including the cerebrovascular circulation (Rasmussen et al.,
2012). The mechanisms had been
proposed to involve EPO-induced release of endothelin (Bode-Böger et
al., 1996) and inhibition of endothelial nitric oxide synthase (eNOS)-

mediated production of nitric oxide
(NO) (Scalera et al., 2005). It was reported that hypertension could aggravate glomerular dysfunction in
Wistar fatty rats fed on high-salt diet
with more generation of reactive oxygen species (ROS) in the kidney
(Tomohiro et al., 2007). So, it is possible that elevation of blood pressure
in EPO-treated diabetic rats promoted renal injury progression in this
study. The present study demonstrated blood pressure-lowering effect of LSR dosage (5 mg/kg, PO) in
diabetic rats which might be considered one of the mechanisms for its
renoprotection. Moreover, blood
pressure-lowering effect of LSR was
reported with the use of lower doses
(2 mg/kg, p.o., 6 weeks) in STZinduced diabetic rats (Murali et al.,
2003).
In the present study, administration of EPO either alone or in combination with LSR to diabetic rats for
28 weeks produced marked increase
of PRacC that was more pronounced
when alone. Previously, it was suggested that circulating EPO levels in
normal subjects had intrinsic renal
effects which were associated with
early marked decrease in circulating
levels of renin and aldosterone (Ol-
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sen et al., 2011). Therefore, we investigated the effects of rHuEPO on
PRacC in control non-diabetic rats
and we found that rHuEPO significantly decreased PRacC (0.5 ± 0.23
pg/ml, P1 < 0.001) in control rats
(data not shown). Previous study
raised the possibility that plasma renin concentrations decreased secondary to a decrease in absolute renal
proximal tubular reabsorption (Olsen
et al., 2011) that in turn increase sodium and water delivery to the macula densa producing inverse changes
in renin release (Burns et al., 1993).
These data were confirmed previously by Lundby et al. (2007) suggesting
that excess rHuEPO may downregulate the activity of RAS independent of changes in red blood cell
mass, blood volumes and blood
pressure thereby maintaining total
blood volume within a narrow range
with the advantage of increasing Hb
faster than by increasing erythropoiesis (Lundby et al., 2007). Administration of LSR alone for 28 weeks
to diabetic rats produced significant
increase of PRacC as angiotensin
receptor blockers through interruption of RAS negative feedback regulation on Ang II results in increases
in plasma Ang II level, which is associated with increase in renin release
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from juxtaglomerular cells (Paul et
al., 2006). At the same time, treatment with ARBs leads to decreased,
rather than increased in kidney Ang
II levels through prevention of AT1
receptor- mediated stimulation of intrarenal angiotensinogen, leading to
decreased intrarenal production of
Ang II and subsequent renoprotection (Nishiyama et al., 2004).
Strangely, plasma EPO concentration was significantly increased in
untreated and EPO-treated diabetic
rats. Administration of LSR in combination with EPO significantly abolished such overshooting of plasma
EPO concentration that even was
significantly decreased compared to
untreated- and LSR-treated diabetic
rats. In support of our results, evidence exists to indicate that prolonged administration of rHuEPO results in a suppression of urinary
excretion of endogenous EPO (Lasne et al. 2002). Additionally and in
agreement with our observations,
EPO levels did not differ significantly
in patients who were on ARB therapy
compared to those who were not
(Mojiminiyi et al., 2006). Also, combined Ang II blockade by captopril
and LSR was associated with reduction in EPO mRNA expression in 5/
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6th nephrectomy rat model (Deng et
al., 2010).
The relationship between rHuEPO administration and RAS is of major concern because RAS regulates
the production of endogenous EPO
(Dunn & Donnelly, 2007). Ang II administration in humans stimulated
EPO synthesis probably through an
AT1-dependent pathway (Gossmann
et al. 2001) and, contrarily, ACE inhibitors (Pratt et al. 1992) and ARBs
decrease the plasma concentration
of endogenous EPO (Durmus et al.
2005). Moreover, studies measuring
levels of PRA and aldosterone during treatment with rHuEPO in patients with CKD and ESRD mostly revealed conflicting results ranging
from unchanged or reduced activity
(reviewed in Rosario & Epstein,
2006). In patients with type 1 diabetes, genetically inherent high activity of the basal RAS was associated
with higher levels of EPO compared
with patients with a low activity of the
basal RAS (Kristensen et al., 2009).
So, it is obvious that the effect of
rHuEPO administration on RAS varies with different disease state and
different medications. Moreover, a
geriatric cohort study found a correlation between higher concentration

of endogenous EPO and fatal outcome which may reflect a physiological response to an undiagnosed hypoxemia or impaired bone marrow
response (den Elzen et al., 2010). In
diabetic patients with CKD, elevated
endogenous EPO levels were predictive for mortality and were related
mainly to markers of inflammation,
independent of kidney function
(Wagner et al., 2011).
In the present study, we measured renal vein oxygen tension (RV
O2T) as an indicator of renal oxygen
consumption and relative hypoxia.
We found that administration of either EPO or LSR for 28 weeks to diabetic rats produced significant improvement of RV O2T compared to
untreated-diabetic control rats; although values remained significantly
lower than control-naïve group.
Combined administration of EPO
and LSR for 28 weeks to diabetic
rats produced more improvement of
RV O2T compared to untreateddiabetic control rats and EPO or LSR
alone-treated diabetic groups. AT1receptor blockade acutely increases
renal cortical PO2 (Norman et al.,
2003) and, if given chronically, losartan attenuated mitochondrial dysfunction in experimental type 1 dia-
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betes (De Cavanagh et al., 2008).
Collectively, these data provide a
mechanistic basis for the use of
ARBs to prevent dysregulation of intrarenal oxygenation in CKD. There
is a strong evidence that hypoxia occurs in diabetic kidney mainly due to
reduced nitric oxide bioavailability as
a result of its quenching by superoxide and increased oxidative stress
(Palm, 2006) which leads to reduced
efficiency of oxygen utilization necessary for electrolyte transport. Nitric
oxide can increase renal oxygenation by increasing oxygen delivery
through vasodilatation (Brezis et al.,
1991) and reducing renal oxygen
consumption by inhibiting tubular sodium reabsorption (Ortiz & Garvin,
2002) and also by competing with
oxygen at the level of cytochrome
oxidase within mitochondria (Koivisto
et al., 1999).
The chronic hypoxia hypothesis
proposed that hypoxic milieu precedes and triggers a fibrotic response leading to renal fibrosis progression (Fine et al., 2000). Renal
hypoxia will stimulate hypoxic gene
response resulting in early cell survival and hypoxia adaptation. Adequate gene response is mediated
through hypoxia-inducible factors
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(HIF) -1 and -2 that regulates numerous target genes, including EPO,
VEGF, hemeoxygenase (HO)-1,
NOS, cyclooxygenase-2, and peroxisome proliferator activated receptor
α-regulated enzyme, which are required in order to normalize tissue
O2 tension (Cummins & Taylor,
2005). However, chronic hypoxia
and even increased HIF expression
may be pro-fibrotic and induce glomerular injury (Higgins et al., 2007
and Ohtomo et al., 2008). HIF induction has been reported to correlate
with tubulointerstitial injury in biopsies from patients with DN (Higgins
et al., 2007). Furthermore, it was hypothesized that hypoxia-induced tubulointerstitial injury may induce interstitial fibrosis and rarefaction of
peritubular capillaries, and that fibrosis in turn would impair the tubular
and interstitial O2 supply. Taken together, these events would constitute a vicious cycle that aggravates
and accelerates renal injury (Palm &
Nordquist, 2011). So the net result is
a vicious circle connecting hypoxia,
inflammation, and fibrosis.
Regarding renal vein electrolytes,
STZ-induced diabetic rats developed
significant decrease of RV Na+ accompanied by significant increase of
MANSOURA MEDICAL JOURNAL
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RV K+ levels compared to control
rats. Administration of EPO to diabetic rats for 28 weeks lowered RV
Na+ and RV K+ than untreateddiabetic control rats, although they
did not reach statistical significance.
So, it seems that sodium and potassium homeostasis is greatly influenced by the diabetic state and renal
function rather than by rHuEPO itself. In agreement with these results,
hyperkalemia was observed in STZinduced diabetic rats 60 days after
induction of diabetes associated with
mild significantly elevated serum
creatinine. The author concluded
multifactorial causes of hyperkalemia
in these diabetic rats including insulinopenia, hyperosmolality, elevated
serum creatinine level and hypoaldosteronism with possible contribution of altered distal tubular response
to aldosterone (Kim, 1994). Studies
in the STZ-induced diabetic rats
showed that Na+-K+-ATPase was affected in several tissues including
kidney. The early phase of diabetes
(up to week 6 or 7), a stimulatory effect on the enzyme was documented
(Fekete et al., 2008). Longer duration of diabetes was followed by a
significant functional depression of
renal Na+-K+-ATPase (Vrbjar et al.,
2004). Numerous explanation of de-

pressed Na+-K+-ATPase included
lack of insulin (Gupta et al., 1996)
and C-peptide (Galuska et al., 2011)
and altered expression of Na+-K+ATPase molecule with long-lasting
diabetes (Tsimaratos et al., 2001).
In the present study, treatment of
diabetic rats with LSR produced significant increase of RV Na+ compared to EPO-treated diabetic rats
accompanied by significant decrease
of RV K+ compared to untreateddiabetic control and EPO-treated diabetic rats. Maintenance of Na+-K+
balance by LSR administration in
STZ-induced diabetic rats copes with
renoprotection observed in this
group. Combined administration of
EPO and LSR for 28 weeks to diabetic rats produced significant increase of RV Na+ compared to EPOtreated diabetic rats accompanied by
significant decrease of RV K+ compared to untreated-diabetic control
rats only; however, it remained significantly higher compared to controlnaïve and LSR-treated diabetic rats.
The possible explanation might be
related to the decrease of intraglomerular capillary pressure in diabetic
kidney by LSR that consequently decreases the pressure natriuresis and
helps to preserve plasma sodium
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(Wolf et al., 2003). However, potassium homeostasis is not maintained
mostly because of overall renal
harmful effects of combination.
We found that rHuEPO (150 U/kg
BW, TIW, SC) for 28 weeks produced significant increase of RBCs
count, Hb concentration, and Hct in
control non-diabetic rats (data not
shown). These results prove that
prolonged chronic administration of
such low dose of rHuEPO is hematologically effective in control rats.
However, this hematopoietic effect
failed to be similarly reproduced in
diabetic rats treated with EPO for 28
week that showed hematological profile nearly similar to untreated diabetic control group. The possible explanation is resistance to exogenously
administered rHuEPO, as well as,
endogenously secreted EPO in the
hyperglycemic environment owing to
chronic low-grade inflammation with
its influence on iron homeostasis (ElKhatib, 2009) and increased oxidative stress (Bamgbola, 2011). A
number of experimental and clinical
studies have demonstrated significant role of various inflammatory
molecules including acute phase reactants, inflammatory cytokines, adhesion molecules, and chemokines
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in the setting of DN (Navarro &
Mora,
2006).
These
proinflammatory cytokines like interleukin-1 and -6, interferon-γ, and tumor
necrosis factor down regulate the expression of EPO receptors on erythroid progenitors and disrupt iron recycling by blocking its release from
reticuloendothelial cells (Macdougall
et al., 2002). Oxidative stress is well
documented in diabetes and may
participate in EPO resistance by
causing lipid peroxidation of red cell
membranes (Gallucci et al., 1999). In
addition, the pro-oxidative renal tissue down regulates the generation
of HIF-1α protein, thereby reducing
EPO synthesis and red cell production (Suliman et al., 2004).
In the present study, inspite untreated and EPO-treated diabetic
rats did not develop anemia, the hematopoietic effect of the administered rHuEPO was different in control and diabetic rats. Moreover,
Body iron status may provide additional evidence to support the new
concept of EPO resistance in this
study. EPO-treated diabetic rats
showed significant decrease of TS
with comparable plasma ferritin compared to untreated-diabetic control
rats denoting the development of
MANSOURA MEDICAL JOURNAL
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functional iron deficiency anemia.
Combination-treated diabetic rats
showed also significant increase of
TS compared to EPO-treated diabetic rats. These results may denote
some sort of resistance to rHuEPO
therapy in hyperglycemic environment. The influence of ACE inhibitors/ ARBs on EPO resistance is
controversial. A range of studies
have either suggested an etiological
role or dismissed it. A prototype
study showed there is a higher EPO
requirement in dialysis patients who
were treated for hypertension with either ACE inhibitors or ARBs compared with those placed on calcium
channel blockers (Nakamoto et al.,
2004). Polymorphism of insertion/
deletion ACE gene was suggested to
have favorable response to ESA in
dialysis subjects (Sharples et al.,
2006). Furthermore, ACE inhibitors
increase plasma level of N-acetylseryl-aspartyllysylproline
(AcSDKP), a naturally occurring inhibitor of erythropoiesis (Le Meur et
al., 2001). In addition, ARBs inhibit
erythroid cellular proliferation by
blocking Ang II binding to AT1 surface receptor (Mohanram et al.,
2008).
Our results also highlight a new

concept in defining EPO resistance
that may occur in certain disease
states without connecting its definition to the presence of anemia or
failure to reach target Hb inspite of
continued rHuEPO therapy. In general, resistance to EPO is presumed in
adult subjects if Hb mass is < 11 g/dl
(over a 4–6-month period) despite a
weekly dose of EPO in excess of
500 IU/kg or 30, 000 IU/week (Bamgbola, 2011).
The condition known as functional
iron deficiency or relative iron deficiency is unique to patients who are
being treated with erythropoiesis
stimulating agents like rHuEPO because their increased rate of RBCs
synthesis overcomes the ability of
transferrin-bound circulating iron to
provide adequate substrate for Hb
synthesis resulting in problem of iron
utilization with low TS while ferritin
level remains normal or elevated
(Wish, 2006). The defective release
of iron from reticuloendothelial cells
could be another responsible factor
in significant number of patients
leading to ineffective EPO therapy.
This reticuloendothelial blockade
usually occurs in the setting of acute
or chronic inflammation and often
correlates with a high C-reactive pro-
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tein level and/or a high erythrocyte
sedimentation rate (Wish, 2006).
Hepcidin is a peptide that is produced by the liver preventing additional exogenous iron absorption and
also inhibits the release of iron from
the Reticuloendothelial (RE) system
to circulating transferrin. Hepcidin
activity is increased in the setting of
inflammation/infection,
primarily
through the release of IL-6 by Kupffer cells in the liver (Ganz, 2003).
This explains the phenomenon of RE
blockade in which storage iron is not
released to circulating transferrin, resulting in a normal or high serum ferritin, low TS level, and reduction in
circulating iron (El-Khatib, 2009).
In the present study, LSR administration for 28 weeks to diabetic rats
led to significant decrease of RBCs
number only, although Hb conc. and
Hct were non-significantly decreased, compared to untreateddiabetic control rats indicating direct
effect on erythropoiesis. Combined
administration of EPO and LSR to diabetic rats produced better hematological profile than administration of
either drug alone, although it is not
statistically significant. Regarding
iron status, LSR-treated diabetic rats
showed plasma ferritin comparable
to control-naïve group. So, iron ho-
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meostasis is not affected by LSR administration. In agreement of our results, ACEIs and ARBs may reduce
Hb concentration in patients with hypertension or CKD. The lowering of
Hb observed during treatment with
ACEIs and ARBs is usually reversible after treatment discontinuation.
The underlying mechanisms are at
least in part related to blockade of
erythropoietic effects of Ang II on red
cell precursors and improved renal
blood flow secondary to renal efferent vasodilation, which improves oxygenation (Marathias et al., 2004). A
post hoc analysis of the RENAAL
Study with an average follow-up of
3.4 years indicated that losartanassociated decline in Hb occurred in
patients with type 2 diabetes and
nephropathy; however, beneficial effects of losartan treatment in this patient population on ESRD and proteinuria persisted in the presence of Hb
decrease (Mohanram et al., 2008).
In conclusion, the present study
stated that LSR is a gold standard
drug in management of DN where it
delayed the progression of albuminuria and stabilized renal function. In
addition, LSR improved diabetic renal hypoxia and prevented hypoxiainduced EPO secretion. Contrarily to
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the expectations, administration of
rHuEPO for 28 weeks led to marked
albuminuria progression with profound increase of PRacC and plasma EPO concentration, together with
picture of acute tubular injury on renal
histopathology
examination.
Clearly, the combination therapy
points to abolishment of the beneficial effect of LSR in experimental DN
by the addition of EPO. This may denote that prolonged administration of
rHuEPO, even in low dose, has intrinsic harmful renal effect mitigating
the effect of a gold standard drug
like LSR. This assumption needs
confirmation at the molecular level in
future experimental studies.
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ا ﻠﺨﺺ اﻟﻌﺮﺑﻰ
دراﺳﺔ ﻃﻮﻳﻠﺔ ا ﺪى ﻟﻺرﺛﺮوﺑﻴﻮﺗ

ﻟﻮﺳﺎرﺗﺎن

واﻻﺛﻨ ﻓﻰ اﳉﺮذان ا ﺼﺎﺑﺔ ﺑﺎﻟﺴﻜﺮى
ا ﺴﺘﺤﺚ ﺑﺎﻹﺳﺘﺮﺑﺘﻮزوﺗﻮﺳ
ﻟـﻘﺪ ﺑﺮز اﻹرﺛﺮوﺑﻮﻳﺘ ) (rHuEPOﻛـﻌﻘﺎر ﺟﺪﻳﺪ ﺣﺎﻣﻰ ﻟﻠﻜﻠﻴﺔ ﺿـﺪ ﻣﺨﺘﻠﻒ اﻹﺻﺎﺑﺎت اﻟﻜﻠﻮﻳﺔ اﳊﺎده.
اﳋـﺒﺮة ﻣﻊ اﻹرﺛﺮوﺑﻮﻳﺘ ﻓﻲ إﺻـﺎﺑﺎت اﻟﻜﻠﻰ ا ﺰﻣﻨﻪ ﺣـﺘﻰ اﻵن ﻣﺤﺪودة ﻣﻊ اﳊﺼﻮل ﻋﻠـﻰ ﻧﺘﺎﺋﺞ ﻣﺘﻀﺎرﺑﺔ .ﻓﻲ
ﻫـﺬه اﻟﺪراﺳﺔ ﺗﻨﺎوﻟﻨﺎ ﺗﻘﻴﻴﻢ اﻵﺛﺎر اﻟﻜﻠﻮﻳﻪ ﻃﻮﻳﻠﺔ اﻷﺟﻞ ﻟﻺرﺛﺮوﺑﻮﻳﺘ ﻓﻰ اﻋﺘﻼل اﻟﻜﻠﻰ اﻟﺴﻜﺮى ﻓﻰ اﳉﺮذان
ﻓـﻴـﻤـﺎ ﻳـﺘـﻌـﻠﻖ ﺑـﻨـﻈـﺮﻳـﺔ ﻧـﻘﺺ اﻷﻛـﺴـﺠـﺔ و إﻓـﺮاز اﻹرﺛـﺮوﺑـﻮﻳـﺘـ اﻟـﺬاﺗﻲ .ﺗـﻤﺖ ﻣـﻘـﺎرﻧـﺔ اﻹرﺛـﺮوﺑـﻮﻳﺘـ إﻟﻰ دواء
ﻗـﻴﺎﺳﻰ ﻟﻮﺳﺎرﺗﺎن ) (LSRو أﻳـﻀﺎ

اﺧﺘﺒﺎر إﻣﻜﺎﻧـﻴﺔ إﺿﺎﻓﺔ ﻛﻼ ﻣﻦ اﻟﻌﻼﺟ ﻣﻌـﺎ.

ﺗﻘﺴﻴﻢ أرﺑﻌﺔ وﺛﻼﺛ

ذﻛـﺮ ﻣﻦ اﳉـﺮذان ﻋﺸـﻮاﺋﻴـﺎ إﻟﻰ ﺧﻤﺲ ﻣـﺠﻤـﻮﻋﺎت :ﻣـﺠﻤـﻮﻋـﺔ ﺿﺎﺑـﻄﺔ ﻣـﺠﻤـﻮﻋﺔ ﺿـﺎﺑﻄـﺔ ﺳﻜـﺮﻳﺔ ﻣـﺠﻤـﻮﻋﺔ
ﺳـﻜـﺮﻳـﺔ ﻣـﻌـﺎﳉـﺔ ﺑـﺪواء اﻹرﺛـﺮوﺑـﻴـﻮﺗ ) 150وﺣـﺪة  /ﻛـﺠـﻢ ﲢﺖ اﳉـﻠـﺪ ﺛﻼث ﻣـﺮات أﺳـﺒـﻮﻋـﻴـﺎ( ﻣـﺠـﻤـﻮﻋﺔ
ﺳـﻜﺮﻳﺔ ﻣﻌﺎﳉـﺔ ﺑﺪواء ﻟﻮﺳﺎرﺗﺎن )  5ﻣـﻠﺞ  /ﻛﺞ  /ﻳﻮم ( ﻣﺠﻤﻮﻋـﺔ ﺳﻜﺮﻳﺔ ﻣﻌﺎﳉـﺔ ﺑﺪواء اﻹرﺛﺮوﺑﻴﻮﺗ ﻣﻊ دواء
ﻟـﻮﺳـﺎرﺗـﺎن .وﻗـﺪ ﺑﺪأ اﻟـﻌﻼج ﻣـﺒـﺎﺷـﺮة ﺑﻌـﺪ اﺣـﺪاث ﻣـﺮض اﻟـﺴﻜـﺮ واﺳـﺘـﻤﺮ  28أﺳـﺒـﻮﻋـﺎ .اﳉﺮذان ا ـﺼـﺎﺑـﺔ ﺑﺪاء
اﻟـﺴـﻜﺮي ا ـﺴﺘـﺤﺚ ﺑـﺎﻹﺳﺘـﺮﺑﺘـﻮزوﺗـﻮﺳ أﺻـﻴﺒﺖ ﺑـﺰﻳـﺎدة اﻷﻟﺒـﻮﻣ ﺗـﺪرﻳـﺠﻴـﺎ ﻓﻰ اﻟﺒـﻮل اﺧـﺘﻼل ﻛﻠـﻮى وﺗﻐـﻴﺮ
ﻛـﺒﻴﺒﻲ ﻛـﺒﻴﺮ ﺑﻌﺪ  28أﺳـﺒﻮﻋﺎ ﻣﻦ اﺣﺪاث ﻣﺮض اﻟـﺴﻜﺮ .اﻻﻋﻄﺎء ا ـﺰﻣﻦ ﻟﻺرﺛﺮوﺑﻮﻳﺘ

 rHuEPOﻟﻮﺣﺪه

أو ﺑـﺎﻻﺷﺘﺮاك ﻣﻊ ﻟﻮﺳﺎرﺗﺎن إﻟﻰ اﳉﺮذان ا ﺼﺎﺑﺔ ﺑﺎﻟﺴﻜﺮي ا ﺴﺘـﺤﺚ ﺑﺎﻹﺳﺘﺮﺑﺘﻮزوﺗﻮﺳ ﻟﻢ ﻳﻈﻬﺮ ﺗﺄﺛﻴﺮ ﻣﻔﻴﺪ
ﻋـﻠﻰ ﺗﻄﻮر اﻋـﺘﻼل اﻟﻜـﻠﻰ اﻟﺴﻜـﺮى ﻋﻠﻲ اﻟﺮﻏﻢ ﻣﻦ ﲢـﺴ ﻧﻘﺺ اﻷﻛـﺴﺠﺔ اﻟـﻜﻠﻮي اﻟـﺴﻜﺮي .ﻟﻮﺳـﺎرﺗﺎن ﻛﻌﻼج
وﺣـﻴﺪ ﻛﺎن ﻟﻪ ﺗﺄﺛﻴـﺮ ﻣﻔﻴﺪ ﻋﻠﻰ ﺗـﻄﻮر اﻋﺘﻼل اﻟﻜﻠﻰ اﻟﺴـﻜﺮى ﻣﻌﺘﻤـﺪا ﻋﻠﻰ ﺗﻘﻴﻴﻢ وﻇـﺎﺋﻒ اﻟﻜﻠﻰ اﻷﻟﺒﻮﻣ ﻓﻰ
اﻟـﺒﻮل وﻓﺤـﺺ اﻟـﻜﻠـﻰ ﻧﺴـﻴﺠﻴ ــﺎ .وﻋــﻼوة ﻋﻠــﻰ ذﻟﻚ اﻋﻄ ــﺎء ﻟﻮﺳﺎرﺗ ــﺎن ﻣﻨﻔـﺮدا أو ﺑﺎﻻﺷﺘﺮاك ﻣﻊ rHuEPO
ﻓـﻰ اﳉـﺮذان ا ـﺼــﺎﺑــﺔ ﺑــﺪاء اﻟـﺴ ـﻜــﺮي ا ـﺴـﺘــﺤﺚ ﺑــﺎﻹﺳ ـﺘــﺮﺑـﺘــﻮزوﺗــﻮﺳ ـ أﻟــﻐﺖ اﻻرﺗـﻔــﺎع اﻟ ـﻜ ـﺒ ـﻴـﺮ ﻓـﻰ ﺑﻼزﻣـﺎ
اﻹرﺛـﺮوﺑـﻮﻳـﺘـ اﻟﺬاﺗﻰ .وﻓـﻰ اﳋﺘـﺎم ﻫـﺬه اﻟـﺪراﺳـﺔ ﺷﻜـﻜﺖ ﻓﻰ اﻟـﺪور اﳊـﺎﻣﻰ ﻟـﻠﻜـﻠﻰ ﻟـﻠـﺠـﺮﻋﺔ ا ـﻨـﺨـﻔـﻀﺔ ﻣﻦ
ﻟـﻺرﺛﺮوﺑﻮﻳـﺘ ﻓﻰ اﻋـﺘﻼل اﻟﻜـﻠﻰ اﻟﺴـﻜﺮى وأﺛـﺒﺘﺖ أن ﻫـﺬه اﳉﺮﻋـﺔ ا ﻨﺨـﻔﻀـﺔ ﻣﻦ اﻹرﺛﺮوﺑـﻮﻳﺘـ ﻛﺎن ﻟـﻬﺎ آﺛﺎر
ﺟﺎﻧﺒﻴﺔ ﻋﻠﻰ ﺿﻐﻂ اﻟﺪم و أدت اﻟﻰ زﻳﺎدة ﻣﺴﺘﻮى اﻟﻬﻴﻤﺎﺗﻮﻛﺮﻳﺖ .(Hct) .
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